TABLE 2.
Summary of results—CBC and immune cell composition in the peripheral blood of patients with malignant melanoma before the beginning of ICI therapy
| Parameter | Responder (R) | Non‐responder (nR) |
|---|---|---|
| Complete blood count, median | ||
| LDH, units/L | 220 | 333 |
| S100, µg/L | 0.1 | 0.1 |
| Platelet count, counts/nl | 241 | 253 |
| Platelet‐to‐lymphocyte ratio | 135 | 289 |
| Lymphocytes and Monocytes, median % | ||
| Lymphocytes | 69 | 50 |
| Monocytes | 15 | 29 |
| Lymphocyte‐to‐monocyte ratio | 5 | 1.6 |
| Regulatory T cells (Treg), median % | ||
| Treg | 3 | 2 |
| CTLA‐4 | 9 | 18 |
| GARP | 26 | 25 |
| HLA‐DR | 82 | 54 |
| T cells, median % | ||
| CD4+ T cells | 63 | 63 |
| Ki‐67 | 1.2 | 0.4 |
| CTLA‐4 | 6 | 14 |
| PD‐1 | 16 | 22 |
| T cell‐to‐Treg ratio | 29 | 43 |
| CD8+ T cells | 15 | 19 |
| Ki‐67 | 28 | 15 |
| CTLA‐4 | 1 | 2 |
| PD‐1 | 16 | 21 |
| T cell‐to‐Treg ratio | 10 | 10 |
| Myeloid‐derived suppressor cells (MDSC), median % | ||
| E‐MDSC | 16 | 16 |
| Arginase 1 | 71 | 52 |
| M‐MDSC | 15 | 16 |
| Arginase 1 | 72 | 61 |
| PMN‐MDSC | 0.2 | 0.5 |
| Arginase 1 | 44 | 56 |
Table 2 summarizes the medians of measured parameters in responders and non‐responders to ICI therapy.
Abbreviations: CTLA‐4, cytotoxic T‐lymphocyte–associated protein; E‐MDSC, early MDSC; GARP, glycoprotein A repetitions predominant; HLA‐DR, human leukocyte antigen‐DR isotype; ICI, immune checkpoint inhibitor; LDH, lactate dehydrogenase; MDSC, myeloid‐derived suppressor cells; M‐MDSC, monocytic/mononuclear MDSC; PD‐1, programmed death receptor‐1; PMN‐MDSC, polymorphonuclear MDSC; S100, S100 protein.